Eesti - eesti - Ravimiamet

berlin-chemie ag - naatriumlevotüroksiin - tablett - 50mcg 50tk; 50mcg 25tk; 50mcg 100tk

Eesti - eesti - Ravimiamet

woerwag pharma gmbh & co. kg - benfotiamiin - kaetud tablett - 50mg 30tk; 50mg 500tk; 50mg 50tk; 50mg 5000tk; 50mg 1000tk; 50mg 100tk; 50mg 60tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - naatriumlevotüroksiin - tablett - 125mcg 50tk; 125mcg 100tk; 125mcg 25tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - naatriumlevotüroksiin - tablett - 150mcg 50tk; 150mcg 100tk; 150mcg 25tk

Eesti - eesti - Ravimiamet

zentiva k.s. - kodeiin+paratsetamool - tablett - 30mg+500mg 30tk; 30mg+500mg 10tk; 30mg+500mg 20tk; 30mg+500mg 100tk; 30mg+500mg 60tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - naatriumlevotüroksiin - tablett - 100mcg 100tk; 100mcg 25tk

Eesti - eesti - Ravimiamet

sopharma ad - luuderohuleht - siirup - 7mg 1ml 120ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaktsiinid - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.